Molecular targets for cancer chemoprevention

Nat Rev Drug Discov. 2009 Mar;8(3):213-25. doi: 10.1038/nrd2663.


Vaccines targeting infections with hepatitis B virus, a risk factor for hepatocellular cancer, and human papillomavirus, a risk factor for cervical cancer, are considered major clinical cancer chemoprevention successes. Molecularly targeted agents can prevent breast cancer (raloxifene and tamoxifen), colorectal adenomas (celecoxib), and prostate cancer (finasteride). Nevertheless, the broad translation of chemoprevention to the clinic is not yet a reality. Continuing research of molecular targets promises to expand the reach of chemoprevention and to personalize it as well.

Publication types

  • Review

MeSH terms

  • Animals
  • Anticarcinogenic Agents / pharmacology
  • Anticarcinogenic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Drug Delivery Systems*
  • Drug Design
  • Humans
  • Neoplasms / etiology
  • Neoplasms / prevention & control*
  • Risk Factors
  • Vaccines / pharmacology
  • Vaccines / therapeutic use


  • Anticarcinogenic Agents
  • Vaccines